Improving health outcomes in 2011 for people with type 2 diabetes: A report from a symposium held on the occasion of the International Diabetes Federation World Diabetes Congress,Dubai,5–8 December 2011

World Health Organization. Diabetes, 2011. www.who.int/mediacentre/factsheets/fs312/en/ (accessed February 2012).

International Diabetes Federation e-atlas of diabetes. Fifth edition, 2011. www.idf.org/diabetesatlas , (accessed February 2012).

International Diabetes Federation. Unite campaign website: http://www.idf.org/worlddiabetesday/the-campaign/unite-for-diabetes (2011, (accessed February 2012).

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.

Holman RR Paul SK Bethel MA . 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359: 1577-89.

Nathan DM Cleary PA Backlund JY . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.

UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.

Nathan DM Buse JB Davidson MB . Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.

Al-Nozha MM Al-Maatouq MA Al-Mazrou YY . Diabetes mellitus in Saudi Arabia. Saudi Med J 2004;25:1603-10.

Al-Nozha MM Al-Mazrou YY Al-Maatouq MA . Obesity in Saudi Arabia. Saudi Med J 2005;26:824-9.

Al-Nozha MM Al-Hazzaa HM Al-Maatouq MA . Prevalence of physical activity and inactivity among Saudis aged 30-70 years. A population-based cross-sectional study. Saudi Med J 2007;28:559-68.

El-Bayoumy I Shady I Lotfy H . Prevalence of obesity among adolescents (10 to 14 years) in Kuwait. Asia Pac J Public Health 2009;21: 153-9.

Central Intelligence Agency. The World Factbook, 2009. https://www.cia.gov/library/publications/the-world-factbook/geos/sa.html , (accessed February 2012).

Pan XR Li GW Hu YH . Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.

Tuomilehto J Lindstrom J Eriksson JG . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.

Knowler WC Hamman RF Edelstein SL . Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150-56.

Chiasson J-L Josse RG Gomis R . Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359:2072-77.

Buchanan TA Xiang AH Peters RK . Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-2803.

Gerstein HC Yusuf S Bosch J . Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096-1105.

Lindström J Ilanne-Parikka P Peltonen M . Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368: 1673-79.

Gaede P Lund-Andersen H Parving HH . Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358: 580-91.

Herrmann W Schorr H Purschwitz K . Total homocysteine, vitamin B(12), and total antioxidant status in vegetarians. Clin Chem 2001;47:1094-1101.

Fernandes CG Borges CG Seminotti B . Experimental evidence that methylmalonic acid provokes oxidative damage and compromises antioxidant defenses in nerve terminal and striatum of young rats. Cell Mol Neurobiol 2011;31:775-85.

Abraham JM Cho L . The homocysteine hypothesis: still relevant to the prevention and treatment of cardiovascular disease? Cleve Clin J Med 2010;77:911-18.

Herrmann W Schorr H Obeid R . Disturbed homocysteine and methionine cycle intermediates S-adenosylhomocysteine and S-adenosylmethionine are related to degree of renal insufficiency in type 2 diabetes. Clin Chem 2005;51:891-97.

Obeid R Kuhlmann MK Köhler H . Response of homocysteine, cystathionine, and methylmalonic acid to vitamin treatment in dialysis patients. Clin Chem 2005;51:196-201.

Saperstein DS Barohn RJ . Peripheral Neuropathy Due to Cobalamin Deficiency. Curr Treat Options Neurol 2002;4:197-201.

Obeid R Kuhlmann M Kirsch CM . Cellular uptake of vitamin B12 in patients with chronic renal failure. Nephron Clin Pract 2005; 99:c42-48.

de Jager J Kooy A Lehert P . Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010; 340:c2181.

National Diabetes Information Clearinghouse. Diabetes Statistics–Complications of Diabetes. 2011. www.niddk.nih.gov/health/diabetes/pubs/dmstats/dmstats.htm#comp (accessed February 2012).

Brownlee M . The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-25

Thornalley PJ . The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Rev 2005;1:287-98.

Kril JJ . Neuropathology of thiamine deficiency disorders. Metab Brain Dis 1996;11:9-17.

Janka HU Rietzel S . Der einflub von neurobion auf die temperatursensibilitat bei patienten mit diabetischer polyneuropathie. In: Rietbrock N (Ed) Pharmakologie und klinische andwedung hochdosierter B-vitamine-steindkopff. Darmstadt: Verlag, 1991, pp.87-97.

Haupt E Ledermann H Köpcke W . Benfotiamine in the treatment of diabetic polyneuropathy–a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 2005;43:71-77.

Stracke H Gaus W Achenbach U . Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008;116: 600-605.

Wong CY Qiuwaxi J Chen H . Daily intake of thiamine correlates with the circulating level of endothelial progenitor cells and the endothelial function in patients with type II diabetes. Mol Nutr Food Res 2008;52:1421-27.

Arora S Lidor A Abularrage CJ . Thiamine (vitamin B1) improves endothelium-dependent vasodilatation in the presence of hyperglycemia. Ann Vasc Surg 2006;20:653-58.

Beltramo E Nizheradze K Berrone E . Thiamine and benfotiamine prevent apoptosis induced by high glucose-conditioned extracellular matrix in human retinal pericytes. Diabetes Metab Res Rev 2009;25: 647-56.

Voziyan PA Metz TO Baynes JW . A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 2002;277:3397-3403.

Robertson J Iemolo F Stabler SP . Vitamin B12, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products. CMAJ 2005;172:1569-73.

Chan JCN Davidson JA . Mechanisms of vascular protection with metformin. In: Bailey CJ Campbell IW Chan JCN . (eds) Metformin: the gold Standard. A scientific handbook. Chichester: Wiley, 2007, pp.135-52.

Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364: 829-41.

Davidson JA Chan JCN . The potential of metformin for the treatment of neoplastic disease. In: Bailey CJ Campbell IW Chan JCN . (eds) Metformin: the gold standard. A scientific handbook. Chichester: Wiley, 2007, pp.245-51.

Zakikhani M Dowling R Fantus IG . Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-73.

Evans JM Donnelly LA Emslie-Smith AM . Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5

Currie CJ Poole CD Gale EA . The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-77.

So WY Yang X Ma RC . Risk factors in V-shaped risk associations with all-cause mortality in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Metab Res Rev 2008;24:238-46.

Yang X Ko GT So WY . Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes 2010;59:1254-60.

Yang X So WY Ma RC . Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 2011;34:375-80.